SLUG and SNAIL as Potential Immunohistochemical Biomarkers for Renal Cancer Staging and Survival.
epithelial–mesenchymal transition
immunohistochemical markers
renal cell carcinoma
slug
snail
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
31 Jul 2023
31 Jul 2023
Historique:
received:
01
07
2023
revised:
20
07
2023
accepted:
25
07
2023
medline:
14
8
2023
pubmed:
12
8
2023
entrez:
12
8
2023
Statut:
epublish
Résumé
Renal cell carcinoma (RCC) is the deadliest urological neoplasm. Up to date, no validated biomarkers are included in clinical guidelines for the screening and follow up of patients suffering from RCC. Slug (Snail2) and Snail (Snail1) belong to the Snail superfamily of zinc finger transcriptional factors that take part in the epithelial-mesenchymal transition, a process important during embryogenesis but also involved in tumor progression. We examined Slug and Snail immunohistochemical expression in patients with different stages of renal cell carcinomas with the aim to investigate their potential role as staging and prognostic factors. A total of 166 samples of malignant renal cell neoplasms were analyzed using tissue microarray and immunohistochemistry. Slug and Snail expressions were evaluated qualitatively (presence or absence), in nuclear and cytoplasmic cell compartments and compared in relation to clinical parameters. The Kaplan-Meier survival analysis showed the impact of the sarcomatoid component and Slug expression on the survival longevity. Cox regression analysis separated Slug as the only independent prognostic factor (
Identifiants
pubmed: 37569620
pii: ijms241512245
doi: 10.3390/ijms241512245
pmc: PMC10418944
pii:
doi:
Substances chimiques
Snail Family Transcription Factors
0
Biomarkers
0
Biomarkers, Tumor
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Wellcome Trust
ID : 200110
Pays : United Kingdom
Références
Rom J Morphol Embryol. 2019;60(2):463-468
pubmed: 31658319
Cell. 2008 May 16;133(4):704-15
pubmed: 18485877
Nat Rev Cancer. 2007 Jun;7(6):415-28
pubmed: 17508028
Cell. 2017 Feb 9;168(4):670-691
pubmed: 28187288
Front Med. 2018 Aug;12(4):361-373
pubmed: 30043221
Cent European J Urol. 2018;71(3):295-303
pubmed: 30386650
Eur Urol. 2012 Jul;62(1):100-14
pubmed: 22381168
Pathobiology. 2016;83(6):277-86
pubmed: 27225469
Mol Oncol. 2017 Jul;11(7):878-891
pubmed: 28544151
BJU Int. 2012 Dec;110(11 Pt C):E1131-7
pubmed: 22712620
Cell. 2009 Nov 25;139(5):871-90
pubmed: 19945376
Oncotarget. 2015 Aug 28;6(25):21406-20
pubmed: 26033551
Cancer Lett. 2014 May 1;346(2):225-36
pubmed: 24384091
Cancer Med. 2020 Mar;9(6):1986-1998
pubmed: 31970942
PLoS One. 2009 Jun 25;4(6):e6039
pubmed: 19557179
Urol Clin North Am. 2023 May;50(2):191-204
pubmed: 36948666
Front Biosci (Landmark Ed). 2009 Jan 01;14(8):3035-50
pubmed: 19273255
J Exp Med. 2019 May 6;216(5):1016-1026
pubmed: 30975895
Cancer Metastasis Rev. 2016 Dec;35(4):645-654
pubmed: 27878502
J Hematol Oncol. 2014 Mar 05;7:19
pubmed: 24598126
Urol Clin North Am. 2008 Nov;35(4):581-92; vi
pubmed: 18992612
Int J Oncol. 2018 Apr;52(4):1139-1148
pubmed: 29532874
Genes Cancer. 2010 Feb 1;1(2):152-163
pubmed: 20871783
Pharmacol Ther. 2015 Jun;150:33-46
pubmed: 25595324
World J Oncol. 2020 Jun;11(3):79-87
pubmed: 32494314
Nat Rev Cancer. 2018 Feb;18(2):128-134
pubmed: 29326430
J Clin Pathol. 2011 Dec;64(12):1088-92
pubmed: 22003062
Cell. 2004 Aug 6;118(3):277-9
pubmed: 15294153
Clin Cancer Res. 2006 Sep 15;12(18):5395-402
pubmed: 17000672
Genes Dev. 1996 Oct 1;10(19):2462-77
pubmed: 8843198
Oncogene. 2013 Jul 4;32(27):3286-95
pubmed: 22847613
BMC Cancer. 2016 Mar 08;16:194
pubmed: 26951092
Neoplasia. 2009 Dec;11(12):1371-82
pubmed: 20019845
Pathologe. 2016 Jul;37(4):355-60
pubmed: 27271258
Cell Adh Migr. 2010 Apr-Jun;4(2):199-203
pubmed: 20168078
Nat Rev Cancer. 2002 Jun;2(6):442-54
pubmed: 12189386
J Natl Cancer Inst. 1997 Sep 3;89(17):1260-70
pubmed: 9293916
Ann Surg Oncol. 2010 Jun;17(6):1471-4
pubmed: 20180029
World J Urol. 2018 Dec;36(12):1913-1926
pubmed: 30123932
Eur Urol. 2018 May;73(5):772-780
pubmed: 29398265
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Urol Oncol. 2015 Feb;33(2):69.e1-10
pubmed: 25218485
Cancer Res. 2007 Oct 1;67(19):9066-76
pubmed: 17909010
J Cell Sci. 2003 Feb 1;116(Pt 3):499-511
pubmed: 12508111
Mol Oncol. 2017 Jul;11(7):718-738
pubmed: 28590039
Lab Invest. 2011 Oct;91(10):1443-58
pubmed: 21808237
Cancer. 2005 Apr 15;103(8):1631-43
pubmed: 15742334